A detailed history of Schroder Investment Management Group transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Schroder Investment Management Group holds 2,923,667 shares of HCM stock, worth $52.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,923,667
Previous 3,024,337 3.33%
Holding current value
$52.5 Million
Previous $51.8 Million 10.39%
% of portfolio
0.06%
Previous 0.06%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$16.03 - $20.31 $1.61 Million - $2.04 Million
-100,670 Reduced 3.33%
2,923,667 $57.2 Million
Q2 2024

Aug 12, 2024

SELL
$16.36 - $21.78 $13.5 Million - $18 Million
-825,456 Reduced 21.44%
3,024,337 $51.8 Million
Q1 2024

May 14, 2024

SELL
$12.08 - $18.56 $3.99 Million - $6.13 Million
-330,043 Reduced 7.9%
3,849,793 $64.7 Million
Q4 2023

Feb 13, 2024

SELL
$16.25 - $20.23 $639,145 - $795,686
-39,332 Reduced 0.93%
4,179,836 $75.7 Million
Q3 2023

Nov 14, 2023

SELL
$11.85 - $16.95 $4.54 Million - $6.5 Million
-383,503 Reduced 8.33%
4,219,168 $71.5 Million
Q2 2023

Aug 11, 2023

BUY
$10.78 - $17.73 $369,829 - $608,263
34,307 Added 0.75%
4,602,671 $55.2 Million
Q1 2023

May 11, 2023

SELL
$13.02 - $19.87 $1.15 Million - $1.76 Million
-88,420 Reduced 1.9%
4,568,364 $59.5 Million
Q4 2022

Feb 10, 2023

BUY
$7.65 - $15.51 $2.42 Million - $4.91 Million
316,388 Added 7.29%
4,656,784 $68.8 Million
Q3 2022

Nov 10, 2022

BUY
$8.63 - $15.52 $7.39 Million - $13.3 Million
855,777 Added 24.56%
4,340,396 $38.5 Million
Q2 2022

Aug 11, 2022

BUY
$8.59 - $20.77 $639,886 - $1.55 Million
74,492 Added 2.18%
3,484,619 $44 Million
Q1 2022

May 16, 2022

BUY
$15.52 - $35.65 $4.78 Million - $11 Million
308,084 Added 9.93%
3,410,127 $67.5 Million
Q4 2021

Feb 14, 2022

BUY
$28.89 - $35.33 $2.08 Million - $2.54 Million
71,992 Added 2.38%
3,102,043 $21.8 Million
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $68.8 Million - $82.9 Million
1,930,312 Added 175.52%
3,030,051 $22.2 Million
Q2 2021

Aug 13, 2021

SELL
$23.7 - $39.27 $69.1 Million - $115 Million
-2,915,949 Reduced 72.61%
1,099,739 $43.2 Million
Q1 2021

May 17, 2021

BUY
$27.01 - $36.8 $2.69 Million - $3.67 Million
99,643 Added 2.54%
4,015,688 $113 Million
Q4 2020

Feb 16, 2021

BUY
$27.51 - $34.36 $2.88 Million - $3.6 Million
104,791 Added 2.75%
3,916,045 $125 Million
Q3 2020

Nov 13, 2020

SELL
$25.8 - $34.61 $6.12 Million - $8.21 Million
-237,138 Reduced 5.86%
3,811,254 $122 Million
Q2 2020

Aug 13, 2020

BUY
$17.65 - $28.05 $1.14 Million - $1.81 Million
64,482 Added 1.62%
4,048,392 $112 Million
Q1 2020

May 15, 2020

BUY
$15.19 - $29.51 $19.5 Million - $37.9 Million
1,285,243 Added 47.63%
3,983,910 $72.8 Million
Q4 2019

Feb 11, 2020

BUY
$17.17 - $25.95 $6.08 Million - $9.19 Million
354,022 Added 15.1%
2,698,667 $67.7 Million
Q3 2019

Nov 12, 2019

BUY
$17.84 - $22.69 $12.7 Million - $16.2 Million
714,434 Added 43.82%
2,344,645 $42.1 Million
Q2 2019

Aug 08, 2019

SELL
$22.0 - $31.78 $4.84 Million - $6.99 Million
-219,813 Reduced 11.88%
1,630,211 $35.9 Million
Q1 2019

May 14, 2019

BUY
$21.27 - $30.58 $979,887 - $1.41 Million
46,069 Added 2.55%
1,850,024 $56.6 Million
Q3 2018

Nov 13, 2018

BUY
$26.55 - $34.38 $7.65 Million - $9.91 Million
288,315 Added 19.02%
1,803,955 $58.1 Million
Q2 2018

Aug 13, 2018

BUY
$27.79 - $34.49 $6.51 Million - $8.08 Million
234,197 Added 18.28%
1,515,640 $46.3 Million
Q1 2018

May 11, 2018

BUY
$28.87 - $41.13 $3.67 Million - $5.23 Million
127,279 Added 11.03%
1,281,443 $37.9 Million
Q4 2017

Feb 09, 2018

BUY
$27.41 - $39.42 $4.3 Million - $6.19 Million
157,000 Added 15.74%
1,154,164 $45.5 Million
Q3 2017

Nov 09, 2017

BUY
$22.15 - $27.5 $22.1 Million - $27.4 Million
997,164
997,164 $27.2 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.